Efficacy and safety of intermittent preventive treatment for malaria in schoolchildren: a systematic review

Malaria Journal

Table 2 Effect of IPTsc on malaria parasitaemia during the intervention period

	Study site	Study by drug regimen	No. of children	Prevalence of infection (%)	PE (95 % CI)
Clarke [24]	Bondo	SP + AQ (four-monthly)	2584	4.6	88 (86 to 90)
		Placebo	2294	39.7	–
Barger [25]	Kollé	SP + AS	91	6.6	81 (56 to 92)
		AQ + AS	97	6.2	81 (57 to 91)
		Placebo	96	34.4	–
Nankabirwa [26]	Tororo	SP	186	79.7	0.05 (−4 to 14)
		SP + AQ	200	43.3	49 (38 to 56)
		DP	198	11.7	86 (80 to 91)
		Placebo	196	84.6	–
Nankabirwa [27]	Tororo	DP (monthly)	2638^a	2	94 (93 to 96)
		DP (three to five monthly)	2644^a	18	54 (49 to 58)
		Placebo	2700^a	38	–

PE protective effect, No number, SP sulfadoxine-pyrimethamine, SP + AQ sulfadoxine-pyrimethamine plus amodiaquine, SP + AS sulfadoxine-pyrimethamine plus artesunate, AQ + AS amodiaquine plus artesunate, DP dihydroartemisinin-piperaquine, % percentage
^aTotal tests

ISSN: 1475-2875